FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Ciaffoni Joseph (Last) (First) (Middle) C/O COLLEGIUM PHARMACEUTICAL, INC. 100 TECHNOLOGY CENTER DRIVE (Street) STOUGHTON MA 02072 (City) (State) (Zip)						2. Issuer Name and Ticker or Trading Symbol COLLEGIUM PHARMACEUTICAL, INC [COLL] 3. Date of Earliest Transaction (Month/Day/Year) 01/25/2019 4. If Amendment, Date of Original Filed (Month/Day/Year)									Relationship of Reporting Person(s) to Issuer Check all applicable) X Director 10% Owner X Officer (give title Other (specify below) President and CEO Individual or Joint/Group Filing (Check Applicable ine) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transacti Date (Month/Day					ction ay/Year)	tion 2A. Deemed Execution Date, if any (Month/Day/Year)			3. Transacti Code (In: 8)	4. Secu		urities Acquired sed Of (D) (Instr.		(A) or	5. Amount of 4 Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock ⁽¹⁾ 01/25/2019 A 90,000 A \$0 198,658 D																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deel Execution if any (Month/		4. Transaction Code (Instr. 8)		on of		6. Date Exei Expiration I (Month/Day	Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)		. 3 ount	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	ly I	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Charle					Code	v	(A)		Date Exercisable		oiration te	Title	Nun of Sha	.					
Option (Right to Purchase)	\$15.9	01/25/2019			A		90,000		(2)	01/	25/2029	Commor Stock	90,	000	\$0	90,000		D	

Explanation of Responses:

- 1. Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Twenty-five percent (25%) of the restricted stock units vest on February 10, 2020, and the balance of the restricted stock units vest in equal annual installments over the following three-year period, subject to the reporting person's continued service with the issuer. The restricted stock units will be settled on each applicable vesting date in shares of the issuer's common stock.
- 2. Twenty-five percent (25%) of the option vests and becomes exercisable on February 10, 2020, and the balance vests in equal quarterly installments (rounded up to the nearest whole share of common stock) over the following three-year period, subject to the reporting person's continued service with the issuer.

Remarks:

/s/ Paul Brannelly as Attorney- 01/29/2019 In-Fact For Joseph Ciaffoni

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.